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Abstract
Synovial biopsies, gained either by blind needle biopsy or minimally
invasive arthroscopy, offer additional information in certain clinical
situations where routine assessment has not permitted a certain
diagnosis. In research settings, synovial histology and modern
applications of molecular biology increase our insight into patho-
genesis and enable responses to treatment with new therapeutic
agents to be assessed directly at the pathophysiological level. This
review focuses on the diagnostic usefulness of synovial biopsies in
the light of actual developments.
Introduction
The possibility of utilizing information from synovial biopsies
as a diagnostic and research tool has attracted substantial
interest amongst rheumatologists in the past few decades
[1,2]. Its importance is likely to further increase in the near
future for a number of reasons. First, early diagnosis and
immediate initiation of disease-modifying antirheumatic drug
(DMARD) therapy in rheumatoid arthritis was shown to
significantly improve outcome parameters [3]. Early rheuma-
toid arthritis (RA), however, may not be unequivocally diag-
nosed in all cases, based on clinical and serological criteria
alone [4]. Histological analysis of synovial biopsies may prove
to be valuable in establishing an early diagnosis [5].
Furthermore, in addition to traditional parameters, histology
and molecular markers out of synovial tissue might be useful
to identify patients with poor outcome [6], provide sensitive
means of assessing response to treatment [7-10], or identify
those patients who most likely will respond to a certain
treatment option [11]. Second, with the actual and upcoming
possibilities of molecular medicine, synovial tissue is needed
to conduct basic research to improve our understanding of
mechanisms of action of modern biological agents and to
develop new therapeutic strategies [12]. Third, images of
modern non-invasive tools such as magnetic resonance
imaging, single photon emission computed tomography, high
resolution duplex sonography, and positron emission com-
puted tomography may be correlated to macroscopic and
histological changes using minimally invasive procedures
such as needle arthroscopy, thereby providing a scientific
basis for future improvements [13]. Fourth, in cases of un-
differentiated arthritis, visualization of the affected joint and
sampling of synovial tissue can facilitate the diagnostic
process [14].
Thus, obtaining a synovial biopsy may likely be an increasingly
important tool in the future, especially from joints that are
involved in the early disease course, such as finger joints.
Complementary to excellent previous reviews of the topic
[1,2], this review will focus on the diagnostic usage and
potential of synovial biopsies.
Synovial sampling
Methods of synovial sampling
Synovial biopsies can be taken by arthroscopy (Figure 1),
using blind needle techniques, or ultrasonographic guidance.
The major draw-back of blind needle biopsy is the potential
for sampling errors. In general, histological results are the
same, regardless of the method used [15]. There is con-
troversy, however, if biopsies from sites adjacent to cartilage,
which cannot be easily biopsied by a blind procedure, display
a higher degree of inflammatory changes, thereby under-
estimating the amount of inflammation and favouring optical
guidance for targeted biopsy [15-18]. Thus, knowledge about
the exact anatomical position of the biopsy may well be
important. Arguments in favour of the use of closed needle
biopsy are the substantially reduced costs as opposed to
arthroscopic procedures and the need for only one rather
than two portals into the joint. Current instrumentation and
techniques of diagnostic arthroscopy have recently been
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reviewed elsewhere [19]. Ultrasonographic guidance of
synovial biopsy is a promising new technique that allows
sampling of large and small joints as well as tendon sheaths
under indirect visualization requiring only one portal [20-22].
Indications in clinical practice
RA can generally be diagnosed based on clinical, serological,
and radiological criteria alone and, for clinical routine purposes,
does not necessitate a biopsy [1,23]. Outside of research
settings, a synovial biopsy can be justified in cases of unclear
arthritis [14,23,24].
Whipple disease can be diagnosed by histological evaluation
of involved organs [25]. If suspected, tuberculous arthritis
should lead to synovial biopsy, especially if synovial culture is
negative for acid-fast bacilli, because super infections with
other organisms may inhibit growth of acid-fast bacilli in
synovial fluid culture [26,27]. Non-infectious granulomatous
states, such as sarcoidosis, affecting a joint can be diag-
nosed when typical histology of the involved synovia is
demonstrated [28]. Malignant cells are sometimes observed
in joint aspiration, but visualization using arthroscopy and
histological evaluation should be undertaken, especially if the
neoplastic process is a metastasis and the primary tumour is
not known [29]. Leukemic arthritis may precede systemic
onset and malignant cells are not always visible in joint
aspiration, especially if hemarthros is present. Synovial biopsy
may demonstrate malignant cell infiltrates in the synovia [30].
Pigmented villonodular synovitis is a differential diagnosis in
mono- or oligoarticular arthritis and biopsy is required for
diagnosis [31]. Pigment deposition as in amyloidosis [32],
ochronosis [33], and hemochromatosis [34] can be diag-
nosed by special staining of the synovial biopsy. Infectious
arthritis may be diagnosed by culturing of biopsy specimen.
The detection of certain infections with pathogens like
Neisseria, Chlamydia, fungi [14,35], and especially infections
with uncommon pathogens such as Varicella zoster virus may
require a biopsy for definitive diagnosis [36]. Diagnosis of
infectious arthritis based on the specific detection of nucleic
acids is also an option, even though results should be
interpreted cautiously, as they are not always of pathogenetic
importance [37]. Deposits of gout and pseudogout can be
detected in synovial tissue [38,39] and are of diagnostic
value in differentiating mass lesions due to crystals from
malignant causes [39].
In rheumatic diseases, arthroscopy may also be indicated for
therapeutic purposes - as in joint lavage of septic arthritis and
rheumatoid arthritis - to remove crystal deposits [40], or for
minimally invasive synovectomy [41]. Furthermore, there are
numerous traumatologic indications for minimally invasive
arthroscopy of joints, such as removal of loose bodies and
fragments of cartilage, but these are beyond the scope of this
review.
Complications
Synovial biopsy is generally regarded as a safe procedure
[1,2]. In a large multicenter survey of over 15,000 arthros-
copies performed by rheumatologists, hemarthros was
reported in 0.9%, wound and joint infection in 0.1%, and deep
vein thrombosis in 0.2% of cases [42]. Complication rates in
blind biopsies are equally low, with no major complications
reported in over 800 blind biopsies in one series [1]. Minimally
invasive joint arthroscopies and blind biopsy may thus safely
be performed in an outpatient setting [17].
Macroscopic assessment of the synovial
membrane
Fiberoptical visualization of joints permits assessment of
bone, cartilage, synovia, and, where present, menisci and
ligaments. Cartilage may be intact, impaired or destroyed;
bony structures may additionally display erosions. The
synovia can be assessed as to its vasculature, proliferation,
presence of synovitis, and thickness (Figure 2). Furthermore,
the presence of chondromatosis and fibrosis can be
detected. By determining these aspects, active and chronic
inflammatory processes and alterations can be differentiated.
Figure 1
Set for mini-arthroscopy (upper) and fiberoptic instrumentation (needle
arthroscopy, diameter 1 mm; lower).Scoring systems for the knee [17] and for metacarpo-
phalangeal joints take into account the above mentioned
alterations [43]. Macroscopic findings were shown to
correlate with histological and clinical parameters [17,44], as
well as magnetic resonance imaging [13] in rheumatoid
arthritis. So far, however, there has been no widely accepted
method for the description or scoring of macroscopic
changes and the suggested scoring systems have not been
validated sufficiently. Furthermore, macroscopic features may
not predict histological changes in individual patients [19].
Macroscopic aspects might help to differentiate different
causes of arthritis, such as distinct vascularity patterns with
straight vessels in RA as opposed to tortuous vessels or a
mixed pattern in spondyloarthritis, reactive arthritis, and
psoriatic arthritis [17,45,46]. These changes, however, are
not sufficiently consistent to permit a diagnosis in individual
patients [45,46]. It is noteworthy that the pattern of
vascularity might be valuable to stratify RA patients into risk
groups with a worse outcome for those who display a straight
vascularity pattern [47]. Further research is needed to deter-
mine the value of macroscopical scoring in arthritis and to
establish standardized scoring systems.
Potential of histopathology derived from
synovial tissue
Histological and molecular markers of inflammation in synovial
tissue correlate with disease activity [48,49], display res-
ponse to treatment [7,8] and permit estimations concerning
disease outcome [6,50] in RA. Intimal layer thickness, blood
vessel proliferation and especially macrophage cell infiltrates
have been pointed out as such synovial markers of disease
activity [51]. Histological assessment of synovial biopsies in
arthritic patients includes the determination of the thickness
of the synovial layer, the density and composition of the
cellular infiltrate, the presence of tumourous structures, and
the presence of bacteria or crystals [52]. The vascularity of
the synovial membrane can also be assessed as and aid in
the differential diagnosis, especially between spondylo-
arthritis and RA [53]. A validated and widely used semi-
quantitative scoring system that focuses on RA takes into
account the degree of subintimal cellular infiltration and
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Figure 2
Intraarticular images of metacarpophalangeal II joints from patients with rheumatoid arthritis. Normal cartilage and synovial membrane after
methotrexate treatment (upper left), cartilage damage and starting erosions (upper right), severe synovial proliferation (lower left), and increased
vascularity (lower right).intimal layer thickness [49]. A more recently introduced
synovitis score additionally requires the quantification of
leukocyte infiltrates and permits the differentiation of inflam-
mation into high-grade and low-grade synovitis in an attempt
to distinguish between different subsets of arthritis, such as
osteoarthritis (low-grade) and RA (high-grade) based on
histological criteria alone [54]. Computer-assisted image
analysis is constantly improving and nowadays permits a
rapid and reliable analysis of tissue sections [55-57].
Histological data have been used to differentiate between
patient groups with different kinds of arthritis in the past [58].
Increased vascularity [53] or the expression of distinct
adhesion molecules [59] may differentiate between
spondyloarthritis and RA, or the cellular composition of the
infiltrate between psoriatic arthritis and RA [53]. Furthermore,
the correct diagnosis in patients with undifferentiated arthritis,
especially the distinction between patients with RA as
opposed to other pathologies, might be facilitated by increased
presence of certain cell subsets [60], molecular markers [5], or
the detection of specific peptides or protein complexes. Intra-
cellular citrullinated proteins and major histocompatibility
complex class II/cartilage glycoprotein complexes detected by
immunostaining of synovial biopsies, for instance, were
demonstrated to be specific, albeit insensitive for RA [61-63]
and might be a useful adjunct to conventional parameters in
the diagnostic workup of patients with undifferentiated
arthritis [64] or in distinguishing those with spondyloarthritis
from those with RA [65] in the future. Ongoing debate about
the specificity of these promising markers [66] underlines the
necessity for further research in this interesting field before
their routine use can be justified. [23]
Histological and molecular findings in early rheumatoid
synovium as well as distinctions between histological and
histochemical findings in early versus late RA have been
extensively reviewed elsewhere [67]. Novel diagnostic markers
can be identified using gene arrays and permit subsequent
targeted research [12]. Further definitions of histological
characteristics and markers to assess response to treatment
in other arthritides such as spondyloarthritis and psoriatic
arthritis are being developed [68,69].
Implications for clinical trials
Synovial biopsies obtained by needle arthroscopy were used
in a number of clinical trials involving various therapeutic
agents and it was shown that changes in synovial histology,
especially the number of CD68-positive sublining macro-
phages, correlate with the effectiveness of the treatment as
determined by the Disease Activity Score (DAS)28 [51].
Furthermore, patients treated with placebo may present a
clinical improvement or change in the DAS28, while the
amount of synovial inflammation represented by inflammatory
cell counts remains high [70,71]. Consequently, the
possibility of a reduction of the number of patients enrolled in
early phase clinical trials using synovial histology rather than
clinical, serological, and radiographic data as response
criteria alone was suggested [1,70]. Synovial biomarkers to
detect responses in clinical trials have been developed [7,8].
Conclusion
As of today, analysis of synovial biopsies in arthritis is fore-
most a research tool at the disposal of facilities equipped
with arthroscopic instrumentation or experienced in blind
biopsy procedures. The analysis of synovial biopsies with
modern methods of molecular biology has increased our
knowledge of disease mechanisms and permits us to
correlate clinical response after the initiation of new thera-
peutic agents with morphological data and transcriptional
changes at the cellular level. Ongoing research aims at
stratifying patients in order to identify those at special risk for
adverse outcome or those that most likely will profit from a
certain treatment option.
In a clinical setting, synovial biopsies are helpful in certain
cases where routine evaluation has failed to suggest a
diagnosis, but the diagnostic spectrum is likely to expand
with ongoing research. Early and specific diagnosis of RA as
well as the distinction of other pathologies associated with
arthritis are future goals.
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